1月22日 - ** 制药商Corcept Therapeutics CORT.O股价盘前上涨19.5%至43.39美元
** 该公司称其试验性抗癌药物relacorilant在铂类耐药性卵巢癌患者的晚期试验中达到了主要目标 (link)。
** 该公司称，该药物与化疗结合使用后，死亡风险降低了 35%
** CORT 公司此前公布了另一项晚期试验的结果 (link)，在该试验中，联合治疗有助于延缓一种卵巢癌的进展。
** Relacorilant 的上市申请目前正在接受美国 FDA 的审查，目标行动日期为 7 月 11 日。
** 2025 年，CORT 下跌了 30.9%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.